Brief: Allarity Therapeutics Announces The Grant Of Essential U.S. Patent For Its Stenoparib Drp® Companion Diagnostic
30/06/2026 13:46
BRIEF-Allarity Therapeutics Announces The Grant Of Essential U.S. Patent For Its Stenoparib Drp® Companion Diagnostic June 30 (Reuters) - Allarity Therapeutics Inc ALLR.O:
ALLARITY THERAPEUTICS ANNOUNCES THE GRANT OF ESSENTIAL U.S. PATENT FOR ITS STENOPARIB DRP® COMPANION DIAGNOSTIC
ALLARITY THERAPEUTICS - GRANTED PATENT TERM EXTENDS INTO APRIL 2042
ALLARITY THERAPEUTICS - HAS PATENT PROTECTION FOR STENOPARIB DRP IN EUROPE AND AUSTRALIA INTO 2039
Source text: ID:nGNX7RPDb3
Further company coverage: ALLR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Allarity Therapeutics
See all newsBrief: Allarity Therapeutics Announces Strategic Capital Allocation For Filing Of Spac Registration Statement
Allarity Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Allarity Therapeutics Q2 loss narrows as expenses fall
Allarity Therapeutics Inc expected to post a loss of 25 cents a share - Earnings Preview
Brief: Allarity Therapeutics Announces The Grant Of Essential U.S. Patent For Its Stenoparib Drp® Companion Diagnostic